Use of recombinant activated factor VII after axillofemoral bypass grafting

Recombinant activated factor VII (rFVIIa) is a powerful prohaemostatic agent that theoretically predisposes to thrombosis after peripheral vascular surgery. We report the use of rFVIIa to reduce bleeding in a patient after axillofemoral bypass grafting for ruptured aorto-iliac pseudoaneurysm. Despit...

Full description

Saved in:
Bibliographic Details
Published in:Anaesthesia and intensive care 2006-06, Vol.34 (3), p.375-378
Main Authors: CHENG, C. A. Y, HO, A. M.-H
Format: Article
Language:English
Subjects:
Anesthesia
Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy
Aneurysm, False - surgery
Aortic Aneurysm, Abdominal - surgery
Biological and medical sciences
Blood Vessel Prosthesis
Factor VII - therapeutic use
Factor VIIa
Hemostatics - therapeutic use
Humans
Iliac Aneurysm - surgery
Male
Medical sciences
Middle Aged
Postoperative Hemorrhage - drug therapy
Recombinant Proteins - therapeutic use
Vascular Surgical Procedures
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Recombinant activated factor VII (rFVIIa) is a powerful prohaemostatic agent that theoretically predisposes to thrombosis after peripheral vascular surgery. We report the use of rFVIIa to reduce bleeding in a patient after axillofemoral bypass grafting for ruptured aorto-iliac pseudoaneurysm. Despite the increased risk of thrombosis, the patient made an uneventful recovery with preserved graft patency. The favourable result suggests that rFVIIa should be considered even in vascular surgical patients, if the risks of continued bleeding outweigh those of thrombosis. Better risk estimation is only possible if reports of rFVIIa use in vascular patients continue to appear and through controlled trials.
ISSN:0310-057X
1448-0271
DOI:10.1177/0310057x0603400301